Hims & Hers Plans Launch of Peptide Treatments Following Federal Policy Shift
Telehealth company Hims & Hers says it plans to begin offering peptide-based treatments this month, becoming one of the largest health care platforms to enter a category that has attracted growing attention from wellness, longevity and medical aesthetics providers.
The company said its initial offerings will include NAD+, sermorelin and glutathione. Andrew Dudum, co-founder and CEO of Hims & Hers, said the company also plans to offer access to BPC-157 and TB-500 if permitted under evolving federal policy.
The announcement follows a recent policy change from the Department of Health and Human Services that would allow compounding of certain peptides while federal rulemaking is underway. According to Hims & Hers, the interim policy creates a pathway for regulated access to some peptide therapies through licensed pharmacies and clinician oversight.
At the same time, the company acknowledged that many peptide products remain supported by limited evidence. In its announcement, Hims & Hers said that much of the current understanding of these compounds is based on early research and clinical experience, and that additional information is still needed about their potential benefits and risks.
The regulatory distinction remains important. The federal government’s recent peptide policy relies on enforcement discretion and does not constitute FDA approval of the compounds for the uses being promoted. Reuters reported that critics of broader peptide access have raised concerns about contamination, impurities and unknown side effects, while supporters argue that regulated domestic access may provide a safer alternative to unregulated products sold online.
Peptides have become increasingly visible in wellness, anti-aging and recovery markets, with compounds such as BPC-157, TB-500 and sermorelin frequently marketed for purposes ranging from injury recovery to healthy aging. However, many of these uses have not been evaluated through the FDA drug approval process.
The development follows a year of heightened attention on peptide regulation. In October, federal officials advanced an interim policy that could expand access to certain compounded peptides while longer-term regulatory decisions are considered. AmSpa previously reported on the FDA’s reevaluation of several peptide substances and ongoing discussions surrounding peptide compounding and safety.
AmSpa Members can access the Peptides Preparedness Resource within the member portal >>
